Executive in Residence
Mr. Tzanis currently serves as the EVP, Head of R&D at Neuraptive Therapeutics. Mr. Tzanis brings over 25 years of global development experience in all aspects of drug development to the company. Prior to joining Neuraptive, Mr. Tzanis served as Chief Development Officer at Paratek Pharmaceuticals, where he led all development activities, including the successful approval of omadacycline (Nuzyra®) and sarecycline (Seysara®). Prior to Paratek, Mr. Tzanis was Head of Development Operations and Biometrics at Endo Pharmaceuticals, where he had leadership responsibility in clinical and project management. During his tenure with Endo Pharmaceuticals, Mr. Tzanis was responsible for several late-stage development programs, including BEMA® Buprenorphine (Belbuca). Prior to joining Endo Pharmaceuticals, Mr. Tzanis had roles of increasing responsibilities at Quintiles (now IQUVIA), Wyeth Pharmaceuticals, and Pfizer. Over his 25 years of experience in the pharmaceutical industry, Mr. Tzanis has been involved in the regulatory approval of ten products among a variety of products designed to treat infectious diseases, dermatology, central nervous system disorders, including panic disorder, major depressive disorder, sleep, pain, as well as opioid-induced constipation and rheumatoid arthritis.